Cargando…
Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201)
BACKGROUND: The efficacy of adjuvant chemotherapy for high-risk stage II colon cancer (CC) has not been well established. We compared the effects of surgery with and without oral uracil and tegafur plus leucovorin (UFT/LV) in patients with high-risk stage II CC, adjusting for potential risk factors....
Autores principales: | Sadahiro, Sotaro, Sakamoto, Kazuhiro, Tsuchiya, Takashi, Takahashi, Takao, Ohge, Hiroki, Sato, Toshihiko, Kondo, Ken, Ogata, Yutaka, Baba, Hideo, Itabashi, Michio, Ikeda, Masataka, Hamada, Madoka, Maeda, Kiyoshi, Masuko, Hiroyuki, Takahashi, Keiichi, Sakamoto, Junichi, Kusano, Mitsuo, Hyodo, Ichinosuke, Taguri, Masataka, Morita, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845390/ https://www.ncbi.nlm.nih.gov/pubmed/35168560 http://dx.doi.org/10.1186/s12885-022-09267-z |
Ejemplares similares
-
Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
por: Sugimoto, Kiichi, et al.
Publicado: (2023) -
Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502
por: Sadahiro, S., et al.
Publicado: (2015) -
Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial
por: Tsuchiya, Takashi, et al.
Publicado: (2014) -
Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial
por: Hasegawa, Kiyoshi, et al.
Publicado: (2016) -
Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer
por: Sadahiro, Sotaro, et al.
Publicado: (2017)